lobbying_activities: 2999110

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2999110	da91088d-6cdc-4e5b-ba56-6d844aa70e14	Q2	RED+BLUE STRATEGIES	400693064	COHERUS BIOSCIENCES	2023	second_quarter	PHA	Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE	50000		0	0	2023-07-05T19:04:30-04:00